# A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma

> **NCT02854839** · PHASE2 · COMPLETED · sponsor: **GC Cell Corporation** · enrollment: 78 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** MG4101

## Key facts

- **NCT ID:** NCT02854839
- **Lead sponsor:** GC Cell Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-28
- **Primary completion:** 2018-09-27
- **Final completion:** 2019-09-17
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02854839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02854839, "A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT02854839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*